# A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

> **NCT05767021** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 172 (actual)

## Conditions studied

- Ulcerative Colitis
- Ulcerative Colitis Chronic

## Interventions

- **DRUG:** Mirikizumab
- **DRUG:** Mirikizumab

## Key facts

- **NCT ID:** NCT05767021
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-17
- **Primary completion:** 2024-08-09
- **Final completion:** 2026-04
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2025-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05767021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05767021, "A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05767021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*